Over 158 applications for generic products pending with USFDA for approval: Lupin

Sharing information with company's shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company's US business stabilised last fiscal and saw an increase of 5 per cent on the back of products like Levothyroxine and Oseltamivir.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3jmoKAn
via IFTTT